Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patientsJoseph Gligorov, Luis Matamala, Beyhan Ataseven et al.|European Journal of Cancer|2017Cited by 47
Histopathologic Diagnostic Agreement Study in Bone and Soft Tissue Tumors: The SELNET Sarcoma Network ExperienceAlberto Righi, Angelo Paolo Dei Tos, Carmen Nieves Hernández-León et al.|JCO Global Oncology|2025Cited by 0